A new treatment that uses the body’s own immune system (immunotherapy), could revolutionise medication for very young children with a moderate to severe form of a common skin condition.
A pioneering method of delivering research – popularised during the height of the COVID-19 pandemic – is being leveraged for the benefit of Greater Manchester residents.
Patients at Manchester University NHS Foundation Trust (MFT) are benefitting from more than 40 combined years of healthcare experience provided by one family of nurses.
The results of the world’s first Phase 3 trials, of a new drug Gefapixant, show that it can ease the often distressing symptoms of chronic cough, with minimal side effects.
The MFT-hosted NIHR Manchester Clinical Research Facility (MCRF) has received a £15.5 million award, widening opportunities for people across Greater Manchester to participate in research.